1 / 8

Nilotinib: A Targeted Drug for Chronic Myelocytic Leukemia Treatment

Nilotinib is a tyrosine kinase inhibitor used in targeted therapy for Chronic Myelocytic Leukemia (CML). It blocks the signals from Bcr-Abl proteins to halt the overgrowth of malfunctioning white blood cells. Despite being a second-generation drug, it offers improved target specificity compared to Imatinib. This medication comes in white/slightly yellowish powder capsules, with FDA approval for marketing in the USA in June 2010. Hong Kong's Hospital Authority is currently considering its approval.

tracief
Download Presentation

Nilotinib: A Targeted Drug for Chronic Myelocytic Leukemia Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Development: Nilotinib Mak Shu Ting (18) Yip Pui Yue (29)

  2. Introduction • a tyrosine kinase inhibitor used targeted therapy for blood cancer , Chronic myelocytic leukemia (CML) • Bcr-Abl protein • Blocks the signals from these proteins • Stop overgrowth of immature, malfunctioning white blood cells

  3. Lead Compound Discovery Imatinib • first-generation drug • inhibit the Bcr-Abl protein to avoid excess white blood cells formation • more and more people had resistant • improving the target specificity of Imatinib

  4. Molecular Modification Imatinib Nilotinib

  5. Working Principle • http://www.youtube.com/watch?v=7ZMVQ1Vbb7Y&NR=1

  6. Safety Tests and Human Trials

  7. Formulation Development • white/slightly yellowish powder • Tasigna (nilotinib) capsules • for oral use • contain 150 mg or 200 mg nilotinib base • FDA recommend that 400 mg orally and twice daily (12 hours apart )

  8. Approval for Marketing • Food and Drug Administration (FDA) approved • In USA: June 2010 • In Hong Kong: Hospital Authority still considering

More Related